Results 41 to 50 of about 17,077 (179)

Esophageal Varices

open access: yes
Meseeha M, Tian C, Attia M.
europepmc   +2 more sources

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang   +20 more
wiley   +1 more source

Microbubble‐Based Ultrasound Contrast Agents in Contrast‐Enhanced Ultrasonography for Managing Portal Hypertension in Cirrhosis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
As the hepatic venous pressure gradient (HVPG) remains the current gold standard for diagnosing portal hypertension in cirrhosis, its clinical application is limited by invasiveness, high cost, and restricted availability. Given the urgent need for noninvasive techniques to dynamically monitor portal vein pressure (PVP), contrast‐enhanced ...
Danping Huang   +5 more
wiley   +1 more source

Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Thrombocytopenia is common in hepatocellular carcinoma and may increase bleeding risk during antiangiogenic therapy, yet the clinically relevant platelet threshold remains uncertain. We found that a baseline platelet count < 50 × 109/L was associated with bleeding; patients below this cutoff had a substantially higher bleeding rate than those with ...
Jun Tie   +8 more
wiley   +1 more source

Study of the effect of vascular endothelial growth factor (VEGF) C(+405)G (rs2010963) single nucleotide polymorphism on the development of esophageal and gastric varices and risk of variceal bleeding in cirrhotic hepatitis C virus (HCV) patients (VEGF) C(+405)G IN esophageal and gastric varices

open access: yesEgyptian Liver Journal, 2022
Background HCV infection is a major worldwide cause of chronic liver diseases. Esophageal and gastric varices are common in cirrhotic patients due to concomitant portal hypertension. Variceal hemorrhage is a major decompensating event with high morbidity
Ashraf Aboismail   +4 more
doaj   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Development of Fundal Varices in Cirrhotic Patients after Eradication of Esophageal Varices

open access: yesJournal of Rawalpindi Medical College, 2017
Background: To analyze the development of fundal varices in cirrhotic patients after eradication of esophageal varices Methods: In this observational study 150 patients of liver cirrhosis, with the history of upper gastrointestinal tract bleed and ...
Muhammad Ajmal
doaj  

ESOPHAGEAL VARICES;

open access: yesThe Professional Medical Journal, 2019
Objectives: To determine the correlation between serum albumin levels and the grades of esophageal varices in patients of liver cirrhosis due to hepatitis B and C. Study Design: Cross-sectional descriptive study. Place and Duration of Study: Unit I, Department of Medicine, Allied Hospital, Faisalabad from 29th June, 2014 to 28th December, 2014 ...
Bilal Aziz, Tazeen Nazar, Nadia Ijaz
openaire   +2 more sources

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

open access: yesHepatology Research, EarlyView.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano   +22 more
wiley   +1 more source

Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

open access: yesHepatology Research, EarlyView.
In patients with cirrhosis and a first portal vein thrombosis treated with intravenous anticoagulant therapy, the 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively. A good radiological response was associated with fewer liver‐related hospitalizations.
Atsushi Maeda   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy